Ropes & Gray has advised Matchpoint Therapeutics on the transaction. Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis for the development...
Matchpoint Therapeutics Enters Into $1 Billion Option and License Agreement with Novartis
Concentra Biosciences to Acquire iTeos Therapeutics in Cash and CVR Transaction
Gibson, Dunn & Crutcher LLP has advised Concentra Biosciences, LLC on the transaction, and Ropes & Gray LLP has advised iTeos Therapeutics, Inc. Concentra Biosciences, LLC...
Pearson to Acquire eDynamic Learning
Ropes & Gray has advised Gauge Capital and eDynamic Learning on the transaction. Gauge Capital and eDynamic Learning have reached an agreement to sell eDynamic Learning,...
IQVIA Completes $2 Billion Senior Notes Offering
Ropes & Gray advised IQVIA Holdings Inc. on the offering; Cahill Gordon & Reindel advised the initial purchasers. IQVIA Holdings Inc. (IQVIA) (NYSE:IQV) has completed a...
InfraBuild’s Consent Solicitation and $150 Million Note Issuance
Ropes & Gray advised InfraBuild on the deal. Herbert Smith Freehills acted as Australian counsel to the ad hoc group of noteholders. InfraBuild, Australia’s only fully...
Valvoline’s $625 Million Acquisition of Breeze Autocare
Squire Patton Boggs advised Valvoline Inc. on the deal, and Kirkland & Ellis advised Greenbriar Equity Group. Valvoline Inc. (NYSE: VVV), an American retail automotive services...
Lepu Biopharma’s $1.6 Billion ADC Licensing Agreement with ArriVent Biopharma
Ropes & Gray represented Lepu Biopharma in the transaction. Shanghai-based Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) announced an exclusive license agreement with ArriVent BioPharma (Nasdaq:...
Arrowhead Pharmaceuticals’ Lincense Collaboration Agreement with Sarepta Therapeutics
Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
Apollo Therapeutics’ Exclusive License Agreement with Sunshine Lake Pharma
Ropes & Gray represented Apollo Therapeutics in the transaction. Apollo Therapeutics Group Limited (“Apollo”) and Sunshine Lake Pharma Co., Ltd. have entered into an exclusive license...
Kailera Therapeutics’ $400 Million Series A Financing
Ropes & Gray advised Kailera Therapeutics, Inc. on the transaction. Kailera Therapeutics, Inc. (“Kailera”) announced raising $400 million in Series A financing. Kailera announced its launch...
Gauge Capital’s Investment in AGT Robotics
Ropes & Gray and Blake, Cassels & Graydon represented Gauge Capital in the transaction. Gauge Capital (“Gauge”) announced its strategic growth investment in AGT Robotics, a...
Pharmacosmos Group’s Acquisition of G1 Therapeutics
Arnold & Porter Kaye Scholer advised Pharmacosmos, while Ropes & Gray and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented G1 Therapeutics on the deal....